CA2759163A1 - Procede de production de l'olmesartan medoxomil - Google Patents
Procede de production de l'olmesartan medoxomil Download PDFInfo
- Publication number
- CA2759163A1 CA2759163A1 CA2759163A CA2759163A CA2759163A1 CA 2759163 A1 CA2759163 A1 CA 2759163A1 CA 2759163 A CA2759163 A CA 2759163A CA 2759163 A CA2759163 A CA 2759163A CA 2759163 A1 CA2759163 A1 CA 2759163A1
- Authority
- CA
- Canada
- Prior art keywords
- olmesartan medoxomil
- reaction mixture
- olmesartan
- water
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-109159 | 2009-04-28 | ||
JP2009109159 | 2009-04-28 | ||
PCT/JP2010/057403 WO2010126013A1 (fr) | 2009-04-28 | 2010-04-27 | Procédé de production de l'olmésartan médoxomil |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2759163A1 true CA2759163A1 (fr) | 2010-11-04 |
CA2759163C CA2759163C (fr) | 2015-02-17 |
Family
ID=43032158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2759163A Active CA2759163C (fr) | 2009-04-28 | 2010-04-27 | Procede de production de l'olmesartan medoxomil |
Country Status (12)
Country | Link |
---|---|
US (1) | US8933241B2 (fr) |
EP (1) | EP2426126B1 (fr) |
JP (1) | JP5595383B2 (fr) |
KR (1) | KR101676512B1 (fr) |
CN (1) | CN102414200B (fr) |
BR (1) | BRPI1013333B8 (fr) |
CA (1) | CA2759163C (fr) |
ES (1) | ES2527686T3 (fr) |
HK (1) | HK1166504A1 (fr) |
IL (1) | IL215966A (fr) |
TW (1) | TWI539948B (fr) |
WO (1) | WO2010126013A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2753874T3 (es) * | 2009-04-28 | 2020-04-14 | Daiichi Sankyo Co Ltd | Cristales de solvato novedosos |
JP2014152127A (ja) * | 2013-02-06 | 2014-08-25 | Tokuyama Corp | オルメサルタンメドキソミルの製造方法 |
CN103719825A (zh) * | 2013-12-19 | 2014-04-16 | 芜湖佳诚电子科技有限公司 | 一种保健香菇粉及其制备方法 |
CN110082449B (zh) * | 2019-05-24 | 2020-05-19 | 珠海润都制药股份有限公司 | 一种奥美沙坦酯中三苯基氯甲烷的检测方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0282519A (ja) | 1988-09-19 | 1990-03-23 | Sanyo Electric Co Ltd | 固相エピタキシャル成長方法 |
US5616599A (en) | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
IS1756B (is) | 1991-02-21 | 2000-12-28 | Sankyo Company Limited | Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða |
JPH07121918A (ja) | 1993-08-30 | 1995-05-12 | Tdk Corp | 光磁気記録媒体 |
JP3521304B2 (ja) | 1996-03-21 | 2004-04-19 | 東洋化成工業株式会社 | 1−(テトラゾリルビフェニルメチル)イミダゾール誘導体の製造方法 |
JP3671266B2 (ja) | 1996-03-21 | 2005-07-13 | 東洋化成工業株式会社 | 5−置換テトラゾール類の製造方法 |
JP2004217542A (ja) | 2003-01-10 | 2004-08-05 | Fuji Photo Film Co Ltd | 4,5−ジアルコキシカルボニルイミダゾールの製造方法 |
CA2513373A1 (fr) | 2003-01-16 | 2004-08-05 | Teva Pharmaceutical Industries Ltd | Nouvelle synthese d'irbesartan |
EP1784398A1 (fr) | 2004-09-02 | 2007-05-16 | Teva Pharmaceutical Industries Ltd | Epuration d'olmesartan medoxomil |
US20070054948A1 (en) | 2004-09-02 | 2007-03-08 | Lilach Hedvati | Purification of olmesartan medoxomil |
CA2573800A1 (fr) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries Ltd. | Preparation d'olmesartan medoxomil |
JP2006111586A (ja) | 2004-10-15 | 2006-04-27 | Nippon Petrochemicals Co Ltd | 置換芳香族化合物の酸化方法 |
US7563814B2 (en) | 2005-01-03 | 2009-07-21 | Teva Pharmaceutical Industries Ltd. | Olmesartan medoxomil with reduced levels of impurities |
EP1910343B1 (fr) | 2005-07-29 | 2014-10-29 | Krka | Procédé de préparation d'olmesartane medoxomil |
SI22092A (sl) | 2005-07-29 | 2007-02-28 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postopek za pripravo olmesartan medoksomila |
WO2007047838A2 (fr) | 2005-10-20 | 2007-04-26 | Dr. Reddy's Laboratories Ltd. | Procede de preparation de l'olmesartan medoxomil |
CZ299902B6 (cs) | 2005-10-27 | 2008-12-29 | Zentiva, A. S | Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv |
WO2007148344A2 (fr) | 2006-06-19 | 2007-12-27 | Matrix Laboratories Limited | Procédé de préparation d'olmésartan médoxomil |
ITMI20061848A1 (it) | 2006-09-27 | 2008-03-28 | Dipharma Spa | Procedimento per la preparazione di composti feniltetrazolici |
JP5269798B2 (ja) | 2006-10-09 | 2013-08-21 | シプラ・リミテッド | トリチルオルメサルタンメドキソミルおよびオルメサルタンメドキソミルの製造方法 |
EP2036904A1 (fr) | 2007-08-08 | 2009-03-18 | LEK Pharmaceuticals D.D. | Procédé pour la préparation d'olmésartan médoxomil |
WO2009019303A2 (fr) | 2007-08-08 | 2009-02-12 | Lek Pharmaceuticals D.D. | Procédé de préparation ou de purification de l'olmésartan médoxomil |
WO2009151016A1 (fr) | 2008-06-09 | 2009-12-17 | 第一三共株式会社 | Procédé de fabrication d’un composé de 1-biphénylméthylimidazole |
EP2334668B1 (fr) | 2008-09-05 | 2014-04-02 | Krka Tovarna Zdravil, D.D., Novo Mesto | Procédé de préparation d'un intermédiaire d'olmésartan médoxomil |
WO2011014611A2 (fr) | 2009-07-30 | 2011-02-03 | Dr. Reddy's Laboratories Ltd. | Préparation de l'olmésartan médoxomil |
US20130190506A1 (en) | 2010-06-28 | 2013-07-25 | Hetero Research Foundation | Process for olmesartan medoxomil |
-
2010
- 2010-04-27 CA CA2759163A patent/CA2759163C/fr active Active
- 2010-04-27 US US13/266,885 patent/US8933241B2/en active Active
- 2010-04-27 ES ES10769711.2T patent/ES2527686T3/es active Active
- 2010-04-27 CN CN201080018897.0A patent/CN102414200B/zh active Active
- 2010-04-27 BR BRPI1013333A patent/BRPI1013333B8/pt active IP Right Grant
- 2010-04-27 JP JP2011511395A patent/JP5595383B2/ja active Active
- 2010-04-27 TW TW099113170A patent/TWI539948B/zh active
- 2010-04-27 KR KR1020117025159A patent/KR101676512B1/ko active IP Right Grant
- 2010-04-27 EP EP10769711.2A patent/EP2426126B1/fr active Active
- 2010-04-27 WO PCT/JP2010/057403 patent/WO2010126013A1/fr active Application Filing
-
2011
- 2011-10-26 IL IL215966A patent/IL215966A/en active IP Right Grant
-
2012
- 2012-07-23 HK HK12107211.4A patent/HK1166504A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2759163C (fr) | 2015-02-17 |
BRPI1013333B8 (pt) | 2021-05-25 |
KR20120006512A (ko) | 2012-01-18 |
ES2527686T3 (es) | 2015-01-28 |
KR101676512B1 (ko) | 2016-11-15 |
EP2426126A1 (fr) | 2012-03-07 |
TWI539948B (zh) | 2016-07-01 |
US8933241B2 (en) | 2015-01-13 |
BRPI1013333B1 (pt) | 2020-10-20 |
BRPI1013333A2 (pt) | 2016-03-29 |
CN102414200A (zh) | 2012-04-11 |
IL215966A (en) | 2014-01-30 |
US20120071665A1 (en) | 2012-03-22 |
CN102414200B (zh) | 2014-12-17 |
IL215966A0 (en) | 2012-01-31 |
WO2010126013A1 (fr) | 2010-11-04 |
JPWO2010126013A1 (ja) | 2012-11-01 |
JP5595383B2 (ja) | 2014-09-24 |
EP2426126A4 (fr) | 2012-10-17 |
HK1166504A1 (en) | 2012-11-02 |
TW201043617A (en) | 2010-12-16 |
EP2426126B1 (fr) | 2014-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2592160A1 (fr) | Olmesartan medoxomil a teneur reduite en impuretes | |
JP5944539B2 (ja) | 新規溶媒和物結晶およびその製造方法 | |
CA2759163C (fr) | Procede de production de l'olmesartan medoxomil | |
WO2012069025A1 (fr) | (5-méthyl-2-oxo-1,3-dioxol-4-ylméthyl)-4-(1-hydroxy-1-méthyl-propyl)-2- propyl-1-[2'-(1h-tétrazol-5-yl)biphényl-4-yl-méthyl]imidazole-5- carboxylate en tant qu'impureté de l'olmésartan médoxomil et son procédé de préparation | |
KR20070086935A (ko) | 불순물의 양이 감소된 올메사탄 메독소밀 | |
KR101134505B1 (ko) | 올메사탄 메독소밀의 제조방법 | |
KR20150004495A (ko) | 올메사탄 메독소밀의 유연물질의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |